CN1059827C - Complex ferrous sulfate tablet - Google Patents
Complex ferrous sulfate tablet Download PDFInfo
- Publication number
- CN1059827C CN1059827C CN 98104770 CN98104770A CN1059827C CN 1059827 C CN1059827 C CN 1059827C CN 98104770 CN98104770 CN 98104770 CN 98104770 A CN98104770 A CN 98104770A CN 1059827 C CN1059827 C CN 1059827C
- Authority
- CN
- China
- Prior art keywords
- ferrous sulfate
- radix
- folic acid
- present
- yeast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000003891 ferrous sulphate Nutrition 0.000 title claims abstract description 63
- 239000011790 ferrous sulphate Substances 0.000 title claims abstract description 63
- 229910000359 iron(II) sulfate Inorganic materials 0.000 title claims abstract description 63
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 title claims 7
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 35
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 27
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 26
- 235000019152 folic acid Nutrition 0.000 claims abstract description 18
- 239000011724 folic acid Substances 0.000 claims abstract description 18
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960000304 folic acid Drugs 0.000 claims abstract description 17
- -1 compound ferrous sulfate Chemical class 0.000 claims abstract description 6
- 229940126680 traditional chinese medicines Drugs 0.000 claims abstract 2
- 239000009636 Huang Qi Substances 0.000 claims description 26
- 229940083563 folic acid 1 mg Drugs 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 5
- 108010052008 colla corii asini Proteins 0.000 claims description 4
- 241000756943 Codonopsis Species 0.000 claims description 3
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 claims description 3
- 244000131316 Panax pseudoginseng Species 0.000 claims description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 3
- MDXRFOWKIZPNTA-UHFFFAOYSA-L butanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)CCC([O-])=O MDXRFOWKIZPNTA-UHFFFAOYSA-L 0.000 claims description 3
- 235000013925 ferrous lactate Nutrition 0.000 claims description 3
- 239000004225 ferrous lactate Substances 0.000 claims description 3
- 229940037907 ferrous lactate Drugs 0.000 claims description 3
- 229960001604 ferrous succinate Drugs 0.000 claims description 3
- 235000008434 ginseng Nutrition 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 2
- 235000013924 ferrous gluconate Nutrition 0.000 claims description 2
- 239000004222 ferrous gluconate Substances 0.000 claims description 2
- 229960001645 ferrous gluconate Drugs 0.000 claims description 2
- 229960001781 ferrous sulfate Drugs 0.000 claims description 2
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims description 2
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 abstract description 58
- 210000004369 blood Anatomy 0.000 abstract description 33
- 239000008280 blood Substances 0.000 abstract description 33
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 abstract description 12
- 230000006870 function Effects 0.000 abstract description 12
- 230000000567 anti-anemic effect Effects 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 abstract description 7
- 208000036581 Haemorrhagic anaemia Diseases 0.000 abstract description 6
- 208000036654 deficiency anemia Diseases 0.000 abstract description 6
- 230000036528 appetite Effects 0.000 abstract description 5
- 235000019789 appetite Nutrition 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 101710186708 Agglutinin Proteins 0.000 abstract description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 abstract description 3
- 101710146024 Horcolin Proteins 0.000 abstract description 3
- 101710189395 Lectin Proteins 0.000 abstract description 3
- 101710179758 Mannose-specific lectin Proteins 0.000 abstract description 3
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 abstract description 3
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 abstract description 3
- 239000000910 agglutinin Substances 0.000 abstract description 3
- 239000003228 hemolysin Substances 0.000 abstract description 3
- 230000000242 pagocytic effect Effects 0.000 abstract description 3
- 244000061520 Angelica archangelica Species 0.000 abstract description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 abstract description 2
- 210000002381 plasma Anatomy 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 230000001079 digestive effect Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 229940126673 western medicines Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 22
- 230000002607 hemopoietic effect Effects 0.000 description 19
- 239000003814 drug Substances 0.000 description 16
- 210000003743 erythrocyte Anatomy 0.000 description 13
- 238000011282 treatment Methods 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 208000007502 anemia Diseases 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 7
- 102000001554 Hemoglobins Human genes 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 6
- 210000002798 bone marrow cell Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940094710 folic acid 1.2 mg Drugs 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CFTOTSJVQRFXOF-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CNCC2 CFTOTSJVQRFXOF-UHFFFAOYSA-N 0.000 description 2
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 240000000073 Achillea millefolium Species 0.000 description 2
- 235000007754 Achillea millefolium Nutrition 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000266851 Hedysarum polybotrys Species 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000003995 blood forming stem cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003013 erythroid precursor cell Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ZXLDQJLIBNPEFJ-UHFFFAOYSA-N tetrahydro-beta-carboline Natural products C1CNC(C)C2=C1C1=CC=C(OC)C=C1N2 ZXLDQJLIBNPEFJ-UHFFFAOYSA-N 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 102000016893 Amine Oxidase (Copper-Containing) Human genes 0.000 description 1
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229940019204 ferrous sulfate 50 mg Drugs 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940095463 folic acid 0.5 mg Drugs 0.000 description 1
- 229940020128 folic acid 1.1 mg Drugs 0.000 description 1
- 229940000252 folic acid 2 mg Drugs 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002984 haematinic effect Effects 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to an antianemic compound ferrous sulfate tablet with the combination of traditional Chinese medicines and western medicines, which is prepared from ferralia, folic acid, yeast and angelica. The present invention can promote the recovery of hemorrhagic anemia, iron-deficiency anemia and nutritional anemia, promote the synthetic action of DNA and RNA of medullary cells, and improve antibody titer, such as the phagocytic function of hemolysin and agglutinin in blood to peritoneal macrophage. The present invention has the functions of promoting appetite, strengthening digestive absorption and fortifying physique. The present invention can promote the absorption of exogenous ferrum, improve the ferrum content in blood plasma and eliminate the adverse reaction of gastrointestinal tracts caused by ferrous sulfate heptahydrate.
Description
The present invention be in, the bonded anti-anemic drug of Western medicine.
Many places become big problem, the especially iron deficiency anemia of community health to nutritional anemia in the world, and extend over the entire globe almost accounts for the 10--20% of world population, and no matter city, rural area, different sexes and all ages and classes person all can get involved.According to China's various places survey result, women's sickness rate is higher, and wherein the adolescence women accounts for 16%, and the adult women accounts for 25-45%, and the women after the amenorrhea accounts for 15-20%; Child, primary and secondary students' nutritional anemia are also very serious.The development of new anti-anemic drug is imperative.Ferrous sulfate is the tradition anti-anemic drug, absorbs easily, and the effective blood concentration height, but digestive tract is had side effect, as feeling sick, vomitting anorexia etc.A kind of ferrous sulfate tablet based on ferrous sulfate is arranged at present, and its ferrous sulfate content is 95-110%, adds an amount of excipient.This Western medicine is oral, and side effect is very big, and the patient is difficult to accept, and a lot of patients are owing to be impatient at, and drug withdrawal midway can not be adhered to treatment and is forced to drug withdrawal.。A kind of in addition " beneficial blood is given birth to " Chinese medicine hematonic mainly is made up of 22 flavor Chinese medicines such as Colla Corii Asini, Sanguis cervi, Placenta Hominis, the Radix Astragali, Radix Rehmanniae Preparata, Radix Angelicae Sinensis, Fructus Jujubae.This pure Chinese medicinal preparation, the hemopoietic effect is very slow, and treatment time is long.Also do not have at present a kind of in, the bonded quick-acting hematopoietics of doctor trained in Western medicine.
The objective of the invention is to overcome above-mentioned in, the shortcoming of Western medicine, provide a kind of novel in, the bonded anti-anemic drug of Western medicine, particularly evident in efficacy to nutritional anemia, hemorrhagic anemia, iron deficiency anemia.
The object of the present invention is achieved like this.The present invention is a complex ferrous sulfate tablet, by chalybeate, folic acid, yeast with when being grouped into.Wherein every contains:
Chalybeate 30--70mg folic acid 0.5--2.5mg
Yeast 70--100mg Radix Angelicae Sinensis 100--150mg (weight portion).
Chalybeate in the above-mentioned prescription can be any in the following stated: ferrous sulfate, ferrous lactate, ferrous succinate, ferrous porphyrin, Melanteritum, ferrous gluconate, dextran ferrum.
Also can add the Radix Astragali in the above-mentioned prescription, its weight portion is 100-150mg.
Also can add in the above-mentioned prescription in the following plurality of Chinese arbitrarily simply: the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae, Radix Codonopsis, Fructus Jujubae, Colla Corii Asini, Radix Polygoni Multiflori, Fructus Lycii, Fructus Corni, Radix Rehmanniae Preparata, Radix Ginseng, Cornu Cervi Pantotrichum, Rhizoma Dioscoreae, VC, Rhizoma Atractylodis etc., weight portion is 100--150mg.
The compound recipe hematopoietic that the present invention is made up of multiple hemopoietic factors such as ferrous sulfate, folic acid, in order to eliminate the side effect that ferrous sulfate brings, the indispensable raw material folic acid of hemopoietic, yeast and Chinese medicine angelica, the Radix Astragali, the Rhizoma Atractylodis Macrocephalae etc. have been increased, can eliminate gastrointestinal reaction, alleviate the side effect of ferrous sulfate, can make other hemopoietic factors play the coordination complementary action again, performance synergism aspect drug effect.The present invention has replenished the multiple hemopoietic factor, quickens the hemopoietic effect, the human body immunity improving function, and facilitating digestion absorbs.Through clinical practice in a few years, have good hemopoietic effect, be subjected to patient's welcome.By clinical practice, the patient has all showed quick-acting hemopoietic effects after using.The low patient of the hemoglobin of 7-8g/100ml blood uses 150-200 grain of the present invention, and 20-30 days, hemoglobin is appreciated reach 11-13g/100ml blood, showed quick-acting hemopoietic effects.
The prescription foundation:
Ferrous sulfate: FeSo
4.7H
2O (FERROSI SULFAS) contains ferrous iron, the content 20% of ferrum, and the absorbance height, cheap, be the main composition of the present invention.Ferrum is the indispensable composition of body, is the component part that constitutes hemoglobin, Myoglobin, cyto-chromatin and histaminase (cytochrome enzyme, cytochrome oxidase, peroxidase, catalase) etc., thereby makes them have the oxygen of carrying and use the oxygen function.
The anemia patient of one individual weight supposition 50kg, every 100ml blood rising hemoglobin 1g needs ferrum 120mg.Computing formula is as follows:
Folic acid: folic acid Yesua ACIDUM FOLICUM is the Main Ingredients and Appearance among the present invention.Folic acid is that hemocyte and mucomembranous cell increase desired substance.Folic acid is reduced to tetrahydrofolic acid (THFA) in vivo, is a carbon-based group carrier, participates in the synthetic of the interior purine of body, thymidylic acid, reaches many metabolic responses such as some aminoacid change.When folic acid deficiency, the biosynthesis of purine, thymidylic acid just can not normally carry out.Some aminoacid change also is obstructed, the DNA biosynthesis block, and the marrow blood nucleus is grown and maturation arrest, causes megaloblastic anemia, and Supplement of folic acid can prevent that anemia from taking place.
Yeast: dry yeast Can jiao mu SACCHAROMYCES SICCUM is one of composition of the present invention.Contain abundant vitamin, protein and aminoacid in the dry yeast.Its contained aminoacid is that body is necessary, and is indispensable when being synthetic protein; Also contain glycine, hemopoietic had facilitation, in the contained multivitamin as VB
12VB
6And folic acid all participates in hemoposieis.It contains very abundant nutrition, has to be good for the stomach, to put in order intestinal, enhancing liver function, and relieving constipation, multiple efficacies such as prophylaxis of cancer, hypertension, diabetes and aging resistance have good facilitation to alleviating ferrous sulfate to gastrointestinal reaction and hemopoietic.
Radix Angelicae Sinensis: Dangui RADIX ANGELICAE SINENSIS is a samphire.The root of Radix Angelicae Sinensis Dangtlicasinensis oliv Diels.The commodity Radix Angelicae Sinensis often is divided into Radix Angelicae Sinensis, Radix Angelicae Sinensis body, Radix Angelicae Sinensis three partly.Ingredient such as uracil, adenine, vitamin B in the Radix Angelicae Sinensis
12, folinic acid, Yan acid etc., all in hematopoiesis, play an important role, vitamin E, β-sitoesterol all play an important role to regulating metabolism in addition.Contain several amino acids and trace element in addition.Hemopoietic all had indispensable effect, as the auxiliary hemopoietic factor of the present invention.
The Radix Astragali: Huangqi RADIX ASTRAGALI is the dry root of leguminous plant Radix Astragali Astragalusmembranac eus (Fisch.) Bge. Radix Astagali Astragalus mambranaceeus Bge.var.mongholius (Bge.) hsiaeo or Hedysarum polybotrys Hand.-Mazz. Hedysarum polybotrys Hand.-Mazz..The Radix Astragali has immunological enhancement, and experiment shows that it can strengthen the phagocytic function of reticuloendothelial system significantly, also can promote healthy people's lymphoblastic transformation function, and promotes the formation of 19s antibody.After the normal person was oral, blood IgM, IgE, cAMP significantly strengthened, and all saw the effect that inducement interferon is arranged at animal and human's body, and clinical research shows that the Radix Astragali can strengthen cellular immunization.The Radix Astragali plays auxiliary hematosis and enhancing human body immunity function in the present invention, so the patient takes when of the present invention, seldom suffers from other disease.
Rhizoma Atractylodis Macrocephalae Baizhu.RHIZOMA ATRACTYCODIS MACRO CEPHALAE is the dry rhizome of feverfew Rhizoma Atractylodis Macrocephalae Atractylodes macyoce-phalaKoidz.Give the Rhizoma Atractylodis Macrocephalae decoct every day mouse stomach, continuous three months laggard line space abdomen swimming tests.Weight increase as a result, and muscle strength reinforcing, preventing cold effect are arranged.The function of the strong health of the said strengthening the spleen and stomach of provable motherland medical science like this.The Rhizoma Atractylodis Macrocephalae helps out in the present invention.
Among the present invention, application experiment animal rat, white mice, rabbit are experimental model, make the model of losing blood, and the iron deficiency anemia model is contrast with original Western medicine ferrous sulfate tablet and pure Chinese medicine " beneficial blood is given birth to ".The result proves that the present invention has ferrum and absorbs soon, iron content height in the blood, and the hemopoietic effect is fast, and invention Peripheral blood examination Hb (hemoglobin), RBC (erythrocyte) are effective more than ferrous sulfate tablet and " beneficial blood is given birth to "; And it is fast to recover the normal blood index, and side effect is little.Following verification experimental verification therapeutic effect of the present invention.
1, the present invention and ferrous sulfate tablet, " beneficial blood is given birth to " have been carried out the hemopoietic effect relatively to white mice hemorrhagic anemia model.
See attached list 1, subordinate list 2, subordinate list 3.
The above results shows, wherein Hb (hemoglobin), RBC (erythrocyte), SI (blood plasma ferrum) are with " beneficial blood is given birth to " the remarkable P of comparing difference＜0.05 to the effect of hemorrhagic anemia in the present invention, and relatively P＜0.01 difference is extremely remarkable with the blank group.
2, the present invention is with " the beneficial blood is given birth to " comparison to medullary cell DAN and RNA anabolic effect influence.
See attached list 4.
The result shows, the present invention organizes the remarkable P of comparing difference＜0.05 to the nucleus formation of mouse bone marrow cells DAN and RNA with " beneficial blood is given birth to ", relatively P＜0.01 difference is extremely remarkable with the blank group, illustrate that the present invention has important facilitation to DAN and RNA are synthetic in the promotion bone marrow, has excitation to the bone marrow hematogenesis function.In the medullary cell division DAN duplicate information representation with RNA, be the synthetic key link of biochemical substances in the body, the intensity of this process indicates the level of bone marrow hematogenesis function, and the mensuration of this index is more more responsive than morphological observation.(this test is with isotope
3H--TdR and the UR method of mixing are carried out).
3, utilize the spleen colony forming method to measure the influence of the present invention to mice pluripotential hemopoietic stem cell CFU-S.
See attached list 5.
The influence that analysis result by experiment, prevention group and matched group relatively form CFU-S is P＜0.05 significant difference relatively.
4, utilize the diffusion chamber method to measure the influence of the present invention to mouse bone marrow cells committed stem cell CFU-C.See attached list 6.
Body internal diffusion basin culture method is to the increase trend that is formed with of mouse bone marrow cells committed stem cell CFU-C, prevention group and control furuncle group colony number of cell CFU-C and the remarkable P of matched group comparing difference＜0.01.This test prompting the present invention has the effect that promotes hemopoietic function, and because of containing Radix Angelicae Sinensis, the Radix Astragali in the prescription, wherein the Radix Angelicae Sinensis polysaccharide composition has the effect that promotes hemocytoblast.Find also that in experiment the present invention has significant promotion appetite, strengthen gastrointestinal function and promote the absorption of exogenous ferrum, and immunologic function is also had in various degree facilitation.As improve in the serum that agglutinin is tired and serum in hemolysin content, and can promote the huge divination by means of the milfoil cell in abdominal cavity gulp down the divination by means of the milfoil activity.The shown promotion immunization of the present invention is relevant with the drug effect of the contained Radix Astragali in the prescription.
5, Patients with iron deficiency anemia is taken ferrous sulfate tablet and is taken every physiochemical indice variation of the present invention and therapeutic effect comparison.
See attached list 7, subordinate list 8.
By last table as can be known, to anemia patient treatment obvious effective rate and ferrous sulfate tablet comparison P＜0.01 significant difference as a result of being grown up.Total effective rate and the remarkable P of matched group comparing difference＜0.01.The present invention is described, and relatively the hemopoietic effect is very obvious with ferrous sulfate.
6, the iron Deficiency Anemia patient is taken ferrous sulfate tablet and take every physiochemical indice variation of the present invention and therapeutic effect comparison.
See attached list 9, subordinate list 10.
By test as can be known: the present invention is with the remarkable P of the poor heteropole of ferrous sulfate tablet group＜0.01; Total effective rate compares P＜0.05 with the ferrous sulfate group, and significant difference illustrate that the anti-anemia effect of the present invention is superior more than ferrous sulfate tablet, and side effect does not show substantially.
The percentage ratio of stomachache among the adult of observation group, nausea and vomiting, poor appetite is respectively 6.54%, 3.69%, 5.53%, and matched group is respectively 11.36%, 31.82%, 36.36%, compared utmost point significant difference for two groups, the present invention and ferrous sulfate tablet side effect be P＜0.01 relatively.Among the child of observation group, the percentage ratio of stomachache, nausea and vomiting, poor appetite is respectively 6.74%, 12.62%, 14.56%, has compared utmost point significant difference and matched group is respectively 37.93%, 68.96%, 74.4%, two group.The present invention and ferrous sulfate tablet side effect be P＜0.01 relatively.
Above-mentioned test has science, advance, practicality.Be used for clinically as anti-anemic drug, obtained fabulous hemopoietic effect, have no side effect again.As be used for anti-anemic drug market, and will extraordinary social benefit be arranged to vast nutritional anemia, hemorrhagic anemia, Patients with iron deficiency anemia, anemia is played the good curing effect; And medicine of the present invention source is abundant, and cost is low, has vast market prospect, can produce good economic benefits.
In a word, the present invention has following effect:
1, can promote the recovery of hemorrhagic anemia, iron deficiency anemia, nutritional anemia.
2, can promote the anabolic effect of medullary cell DNA and RNA.
3, the formation to bone marrow committed stem cell CFU-C and spleen hemopoietic colony pluripotential hemopoietic stem cell CFU-S has facilitation.
4, have immunological enhancement, can improve antibody titer, reach the peritoneal macrophage phagocytic function as hemolysin, agglutinin in the blood.
5, promotion appetite is arranged, strengthen the effect of digesting and assimilating with strong body constitution.
6, can promote the Absorption of exogenous ferrum, improve the content of ferrum in the blood, eliminate the gastropore intestinal untoward reaction that ferrous sulfate causes.
The present invention is provided by following examples.
Embodiment 1: iron dextran 50mg
Folic acid 1mg
Yeast 84mg
Radix Angelicae Sinensis 120mg
Radix Astragali 120mg (weight portion).Embodiment 2: ferrous lactate 50mg
Folic acid 1mg
Yeast 84mg
Radix Angelicae Sinensis 120mg (weight portion).Embodiment 8: ferrous succinate 50mg
Folic acid 1mg
Yeast 84mg
Radix Angelicae Sinensis 120mg
Radix Astragali 120mg
Radix Ginseng 120mg (weight portion).Embodiment 4: ferrous sulfate 50mg
Folic acid 1mg
Yeast 84mg
Radix Angelicae Sinensis 120mg
Radix Astragali 120mg
Pericarpium Citri Reticulatae 120mg (weight portion).Embodiment 5: Melanteritum 50mg
Folic acid 1mg
Yeast 84mg
Radix Angelicae Sinensis 120mg
Radix Astragali 120mg
Radix Codonopsis 120mg (weight portion).Embodiment 6: ferrous porphyrin 70mg
Folic acid 0.5mg
Yeast 100mg
Radix Angelicae Sinensis 100mg
Radix Astragali 110mg
Fructus Lycii 120mg (weight portion).Embodiment 7: ferrous sulfate ferrum 60mg
Folic acid 1.5mg
Yeast 90mg
Radix Angelicae Sinensis 110mg
Radix Astragali 120mg
Rhizoma Atractylodis 100mg (weight portion).Embodiment 8: ferrous sulfate ferrum 40mg
Folic acid 1.2mg
Yeast 95mg
Radix Angelicae Sinensis 120mg
Radix Astragali 120mg
Colla Corii Asini 120mg (weight portion).Embodiment 9: ferrous sulfate ferrum 50mg
Folic acid 1mg
Yeast 84mg
Radix Angelicae Sinensis 120mg
Radix Astragali 120mg
Rhizoma Atractylodis Macrocephalae 100mg (weight portion).Embodiment 10: ferrous sulfate ferrum 55mg
Folic acid 1.2mg
Yeast 90mg
Radix Angelicae Sinensis 115mg
Radix Astragali 110mg
Fructus Corni 120mg (weight portion).Embodiment 11: ferrous sulfate ferrum 55mg
Folic acid 2mg
Yeast 93mg
Radix Angelicae Sinensis 130mg
Radix Astragali 115mg
Radix Rehmanniae Preparata 120mg (weight portion).Embodiment 12: ferrous sulfate ferrum 45mg
Folic acid 1.1mg
Yeast 93mg
Radix Angelicae Sinensis 105mg
Radix Astragali 106mg
Cornu Cervi Pantotrichum 115mg (weight portion).Embodiment 13: ferrous sulfate ferrum 35mg
Folic acid 1.4mg
Yeast 94mg
Radix Angelicae Sinensis 112mg
Radix Astragali 112mg
Rhizoma Dioscoreae 110mg (weight portion).Embodiment 14: ferrous sulfate ferrum 65mg
Folic acid 1.2mg
Yeast 80mg
Radix Angelicae Sinensis 125mg
Radix Astragali 120mg
VC 120mg (weight portion).Embodiment 15: ferrous sulfate ferrum 38mg
Folic acid 1.3mg
Yeast 92mg
Radix Angelicae Sinensis 114mg
Radix Astragali 124mg
Rhizoma Atractylodis 120mg (weight portion).
Table 1 complex ferrous sulfate tablet is to the effect of enriching blood of mouse blood loss anemia
Annotate: with control group relatively * P＜0.05 * * P＜0.01 table 2 complex ferrous sulfate tablet and ferrous sulfate tablet to the hematosis of mouse blood loss anemia
Annotate: compare * P＜0.05 with control group. The routine blood test of table 3 pair hypoferric anemia animal and the impact of ferro concentration in serum
| Group | Dosage mg/kg | The mouse number | RBC ten thousand/mm3 | Hb g/100ml | ||||
| Before losing blood | After losing blood | After the administration | Before losing blood | After losing blood | After the administration | |||
| Control group benefit blood is given birth to complex ferrous sulfate tablet complex ferrous sulfate tablet complex ferrous sulfate tablet | 3000 1983 991 496 | 12 12 12 12 12 | 923±10.1 921±16.6 902±22.8 908±13.6 891±18.9 | 691±20.8 720±24.8 724±17.3 680±17.4 702±24.6 | 738±18.3 786±27.3 814±19.4* 780±12.2 770±17.3 | 11.0±0.28 11.0±0.4 11.0±0.43 11.3±0.26 11.0±0.2 | 8.0±0.24 8.5±0.23 8.1±0.16 7.8±0.26 7.8±0.2 | 10.0±0.32 11.5±0.34 12.6±0.2 11.8±0.16 11.3±0.43* |
| Group | Dosage mg/kg | Animal (only) | Before losing blood | After losing blood | After the administration | |||
| RBC | Hb | RBC | Hb | RBC | Hb | |||
| Control group ferrous sulfate tablet complex ferrous sulfate tablet complex ferrous sulfate tablet | 300 1800 900 | 10 10 10 10 | 714±43.5 700±52.2 703±33.4 717±34.7 | 11.8±0.54 11.9±0.62 12.0±0.71 12.0±0.73 | 556±52.5 541±56.3 561±59.5 567±44.5 | 8.2±0.86 8.4±0.71 8.3±0.75 8.1±0.78 | 673±70.2 733±46.7* 744±4363* 719±45.5 | 9.4±0.81 11.4±0.85* 11.8±0.43* 11.1±0.73 |
| Group | Dosage mg/kg | The mouse number | Hb g/100ml | RBC ten thousand/mm3 | SI μg/ml |
| Normal group control group benefit blood is given birth to complex ferrous sulfate tablet complex ferrous sulfate tablet complex ferrous sulfate tablet | 3000 1983 991 496 | 10 10 10 10 10 10 | 12.5±0.35 10.8±0.27 12.9±0.05 14.7±0.55 11.8±0.26 11.6±0.18 | 766±30.6 640±27.5 728±26.9 825±27.5 685±25 673±14.9 | 9.4±1.95 8.1±1.75 12.2±1.0* 12.7±1.15* 11.2±0.41 9.5±2.5 |
The result shows: the equal contrast group of the RBC of complex ferrous sulfate tablet experimental group, Hb and ferro concentration in serum height shows Complex ferrous sulfate tablet can make the iron nutritional status of edible low iron animal improve.
Table 4 complex ferrous sulfate tablet is to the impact of bone marrow cell DNA and RNA synthesis
| Group | Dosage mg/kg | The mouse number | DNA nMOL/1×10 6 cell | RNA nMOL/1×10 6cell |
| Control group benefit blood is given birth to complex ferrous sulfate tablet complex ferrous sulfate tablet complex ferrous sulfate tablet | 3000 1983 991 496 | 10 10 10 10 10 | 0.046±0.005 0.082±0.01** 0.169±0.03** 0.136±0.02** 0.062±0.012 | 0.036±0.004 0.077±0.002* 0.201±0.022** 0.074±0.008* 0.053±0.004 |
The result shows: complex ferrous sulfate tablet synthesizes at LD DNA, the RNA's of bone marrow cell501/5 and 1/10 Facilitation is all arranged during dosage. Low dose group LD501/20 also have promote trend that DNA, RNA are synthetic but with contrast Group does not relatively have significant difference. The impact that table 5 complex ferrous sulfate tablet forms animal spleen hematopoiesis colony (CFU-S)
Table 6 complex ferrous sulfate tablet is to the impact of bone marrow cells in mice (CFU-C)
| Group | Dosage mg/kg | Sample number | Colony is counted the CFU-S/ spleen | The P value |
| Control group prevention group treatment group | 1983 1983 | 20 20 20 | 11.6±2.4 21±3.2 18.1±2.0 | ＜0.05 ＜0.05 |
| Group | Dosage mg/kg | Sample number | CFU-E productive rate (individual/105) | Xi Bao Ji Cutters number |
| Control group prevention group treatment group | 1983 1983 | 20 20 20 | 63±6.0 110±11.7** 80±7.4 | 52±5.5 90±8.0* 79±17.9 |
Annotate: compare * P＜0.05 * * P＜0.01 with control group
The result shows: the CFU-S of two administration groups and the measured value of CFU-E, and with relatively having obviously with control group Difference. The prompting complex ferrous sulfate tablet has certain facilitation to the mouse bone marrow cells hematopoietic function.
Table 7 Patients with iron deficiency anemia is treated forward and backward every blood index (X ± S)
Hb and control group 2 compare ※ p＜0.05 MCHC and control group 1.2 compares ※ p＜0.05 TIBC and control group 1.2 compares ※ p＜0.05
| Group | Before the treatment | After the treatment | ||||||||||||||
| 11b (g/L) | RBC (×10 12/L) | MCV (fL). | MCH (pg) | MCHC (pg/L) | SI (μg/dl) | THBC (μg/dl) | SF (μg/dl) | Hb (g/L) | RDC (×10 12/L) | MCV (IL) | MCH (pg) | MCHC (pg/L) | SL (μg/dl) | TIBC (μg/dl) | SF (μg/L) | |
| Observation group | 74.5±14.8 | 3.465±0.778 | 71.14±3.45 | 24.03±1.63 | 302.83±4.75 | 42.1±21.0 | 450.3±83.5 | 8.28±5.67 | 125.0±14.2 | 4.443±0.534 | 86.14±0.26 | 32.01±0.14 | 340.16±4.12 | 87.6±37.6 | 334.3±56.71 | 26.26±24.10 |
| Control group 1 | 76.4±13.6 | 3.679±0.600 | 73.26±4.15 | 26.03±2.16 | 304.76±3.64 | 45.0±21.4 | 444.8±65.2 | 8.72±6.38 | 117.8±13.9 | 4.477±0.488 | 83.21±0.34 | 31.11±0.16 | 328.46±4.13 | 91.4±32.6 | 354.3±58.7 | 25.21±26.50 |
| Control group 2 | 78.4±12.6 | 3.644±0.668 | 74.34±3.16 | 26.04±3.15 | 305.12±2.7 | 43.5±16.7 | 468.7±74.4 | 8.48±5.66 | 114.7±15.5 | 4.483±0.547 | 80.87±0.26 | 30.64±0.18 | 21.16±0.39 | 80.2±27.3 | 372.3±66.2 | 20.48±13.96 |
The treatment results of table 8 Patients with iron deficiency anemia
| Group | The example number | Produce effects example number (%) | Effective routine number (%) | Invalid routine number (%) | Total effective routine number (%) |
| Observation group's control group 1 control group 2 | 217 97 83 | 197(90.78) 79(81.44) * 59(71.08) ** | 10(4.61) 8(8.25) 10(12.05) | 10(4.61) 10(10.31) 14(16.87) | 207(95.39) 87(89.69) 69(83.12) ** |
Observation group's obvious effective rate and control group 1 than * p＜0.05 total effective rate and control group 2 than * * p＜0.01
Observation group's obvious effective rate and control group 2 are than * * p＜0.01
The forward and backward every blood index of table 9 iron Deficiency Anemia patient treatment (X ± S)
* compare p＜0.01 with control group
| Group | Before the treatment | After the treatment | |||||||||||||||
| Hb (g/L) | RBC (×10 12/L) | MCV (IL) | MCH (pg) | MCHC (Pg/L) | SI (μg/dl) | TIBC (μg/dl) | SF (μg/L) | Hb (g/L) | RBC (×10 12/L) | MCV (fL) | MCH (pg) | MCHC (pg/L) | SI (μg/dl) | THBC (μg/dl) | SF (μg/L) | ||
| Observation group | 74.7±11.7 | 3.301±0.858 | 78.16±1.6 | 27.12±1.21 | 30.12±2.25 | 53.3±9.5 | 391.5±216.1 | 7.72±1.64 | 133.1±0.9* | 4.821±0.883 | 90.12±7.5 | 32.11±3.51 | 34.14±4.21 | 124.64±32.9* | 335.7±20.2 | 14.14±1.46 | |
| Control group | 71.0±4.8 | 3.237±0.247 | 77±1.3 | 26.21±1.34 | 30.14±2.45 | 43.6±7.7 | 662.1±253.7 | 7.70±0.88 | 116.6±12.5 | 4.617±0.297 | 88.10±1.6 | 31.12±3.91 | 3.16±3.74 | 69.6±15.4 | 430.7±163.2 | 13.62±1.85 | |
The treatment results of table 10 Irondeficiencyanemia (X ± S)
| Group | The example number | Produce effects example number (%) | Effective routine number (%) | Invalid routine number (%) | Overall rate (%) |
| Observation group's control group | 103 29 | 98(95.15)** 19(65.51) | 1(0.97) 6(20.68) | 4(3.88) 4(13.79) | 99(96.12)* 25(86.21) |
* p＜0.05 (total effective rate) * * p＜0.01 (observation group's obvious effective rate and control group obvious effective rate relatively have significant difference)
Claims (5)
1, a kind of complex ferrous sulfate tablet is characterized in that it makes by the chalybeate of following weight proportion, folic acid, yeast with when being classified as raw material, wherein: and chalybeate 30-70mg,
Folic acid 0.5-2.5mg,
Yeast 70-100mg,
Radix Angelicae Sinensis 100-150mg.
2,, it is characterized in that chalybeate can be any of the following stated according to the described complex ferrous sulfate tablet of claim 1; Ferrous sulfate,
Ferrous lactate,
Ferrous succinate,
Ferrous porphyrin,
Melanteritum,
Ferrous gluconate or
Dextran ferrum.
3, according to the described complex ferrous sulfate tablet of claim 1, it is characterized in that it makes by the chalybeate of following weight proportion, folic acid, yeast with when being classified as raw material, wherein: chalybeate 50mg,
Folic acid 1mg,
Yeast 84mg,
Radix Angelicae Sinensis 120mg.
4, according to the described complex ferrous sulfate tablet of claim 1, it is characterized in that can increasing the Radix Astragali in the raw material, its weight portion is 100-150mg.
5, according to the described complex ferrous sulfate tablet of claim 4, it is characterized in that can increasing in the raw material in the following traditional Chinese medicines simply: the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae, Radix Codonopsis, Fructus Jujubae, Colla Corii Asini, Radix Polygoni Multiflori, Fructus Lycii, Fructus Corni, Radix Rehmanniae Preparata, Radix Ginseng, Cornu Cervi Pantotrichum, Rhizoma Dioscoreae, Vc, Rhizoma Atractylodis, weight portion are 100-150mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 98104770 CN1059827C (en) | 1998-02-17 | 1998-02-17 | Complex ferrous sulfate tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 98104770 CN1059827C (en) | 1998-02-17 | 1998-02-17 | Complex ferrous sulfate tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1190589A CN1190589A (en) | 1998-08-19 |
| CN1059827C true CN1059827C (en) | 2000-12-27 |
Family
ID=5218445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 98104770 Expired - Lifetime CN1059827C (en) | 1998-02-17 | 1998-02-17 | Complex ferrous sulfate tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1059827C (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101269128B (en) * | 2008-05-12 | 2012-02-22 | 北京冠五洲生物科学研究院 | Pharmaceutical combination for preventing birth defect and improving anamnesis |
| CN101269148B (en) * | 2008-05-12 | 2012-02-22 | 北京冠五洲生物科学研究院 | Pharmaceutical combination for preventing birth defect and improving anamnesis |
| CN101375906B (en) * | 2008-09-26 | 2012-07-04 | 北京冠五洲生物科学研究院 | Pharmaceutical combination for preventing birth-defect and improving memory |
| CN102138943B (en) * | 2011-03-30 | 2014-03-12 | 冯金民 | Traditional Chinese medicinal preparation for treating anemia |
| CN102552455A (en) * | 2011-10-13 | 2012-07-11 | 宁波海逸生物科技有限公司 | Formula for health care medicine capable of improving nutritional anemia and enhancing immunity |
| CN102552435B (en) * | 2011-10-13 | 2014-05-07 | 宁波海逸生物科技有限公司 | Health-care medicinal formula for improving alimentary anemia and enhancing immunity |
| CN102872186B (en) * | 2012-10-31 | 2014-02-26 | 吉林省西点药业科技发展股份有限公司 | Production method of compound ferrous sulfate and folic acid tablets |
| CN102920834A (en) * | 2012-11-23 | 2013-02-13 | 深圳市佳泰药业股份有限公司 | Lvrong blood nourishing capsule and preparation method thereof |
| CN103432272A (en) * | 2013-08-26 | 2013-12-11 | 费海荣 | Compound medicine for treating hypoferric anemia and preparation method thereof |
| CN103655574A (en) * | 2013-12-20 | 2014-03-26 | 合肥九研医药科技开发有限公司 | Compound ferrous succinate and folic acid composition |
| CN104825681A (en) * | 2015-05-23 | 2015-08-12 | 周末 | Traditional Chinese medicine composition for improving alimentary anemia |
| CN104857179A (en) * | 2015-05-23 | 2015-08-26 | 张家港市五湖新材料技术开发有限公司 | Traditional Chinese medicine composition capable of improving nutritional anemia |
| CN109793820A (en) * | 2017-11-16 | 2019-05-24 | 江西康宝医药生物科技有限公司 | Using ginseng as primary raw material blood-enrich oral solution |
| CN112641878A (en) * | 2020-12-11 | 2021-04-13 | 建昌帮药业有限公司 | Traditional Chinese medicine composition for treating anemia and preparation method thereof |
| CN115068553A (en) * | 2021-12-09 | 2022-09-20 | 宝健（北京）生物技术有限公司 | Pharmaceutical composition for replenishing blood, tonifying qi and strengthening spleen, preparation and application thereof |
-
1998
- 1998-02-17 CN CN 98104770 patent/CN1059827C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1190589A (en) | 1998-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1059827C (en) | Complex ferrous sulfate tablet | |
| CN1056073C (en) | Nutritious health-care oral liquor | |
| CN1759877A (en) | Composition of medication for treating anemia, and application | |
| CN1228074C (en) | Chinese traditional medicine for treating immune hypofunction and disfunction | |
| CN106509887A (en) | Fatigue preventing health-care composition and a preparation method thereof | |
| CN1062474C (en) | Glossy ganoderma-Eighteen treasure oral liquid | |
| CN1743002A (en) | Iron-supplementing preparation | |
| CN1097998A (en) | Shengliyangshengye-nourishing liquid for building up strength | |
| CN101273775A (en) | Cordyceps mycelium capsules and producing process thereof | |
| CN109731075A (en) | Grow Chinese medicine composition, cell nutritious element and the application method of pancreas nourishing the liver control sugar therapy | |
| CN1173711C (en) | Doukey-hide gelatin capsule | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN1478508A (en) | Chinese medicinal composition for treating fatty liver and its preparation method | |
| CN1317033C (en) | Blood nourishing body building composition and its production method | |
| CN1063649C (en) | Red ginseng and hawthorn fruit health-care wine | |
| CN1274363C (en) | Auxiliary therapeutic agent for C type hepatitis | |
| CN1883641A (en) | Anti-ageing body-strengthening medicine for treating spleen-kidney yang deficiency and preparation method thereof | |
| CN1562272A (en) | Medication for curing secondary anemia, iron deficiency anemia and preparation method | |
| CN1586331A (en) | Multifunctional fat reducing nutrition regimen drink | |
| CN1432374A (en) | Kidney asthenia treating medicine and its prepn process | |
| CN106387363A (en) | Iodine-enriched selenium-enriched chromium-enriched strengthening agent for eggs, as well as preparation method and use method of iodine-enriched selenium-enriched chromium-enriched strengthening agent | |
| CN1513500A (en) | Liu-Wei-Bu-Xue granule for invigorating blood contg. six herbal medicines and its prepn. method | |
| CN1850265A (en) | Chinese medicine for treating nephrosis Yang deficiency syndrome | |
| CN100339133C (en) | Composition of nanometer SOD and astragalus root or its extract and its preparation method | |
| CN1931256A (en) | Chinese medicine capsule for eliminating drug addiction and its prepn process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Applicant after: Guan Tianying Applicant after: Wang Yuzhi Applicant after: Liu Shuzhen Applicant after: Jilin Agricultural University Applicant before: Guan Tianying Applicant before: Wang Yuzhi Applicant before: Liu Shuzhen |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: GUAN TIANYING; WANG YUZHI; LIU SHUZHEN TO: GUAN TIANYING WANG YUZHI LIU SHUZHEN; JILIN AGRICULTURAL UNIVERSITY |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Guan Tianying Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice |
Addressee: Wang Yuzhi Document name: Notification of Termination of Patent Right |
|
| ASS | Succession or assignment of patent right |
Owner name: XIDIAN PHARM IND TECH DEVELOPMENT CO., LTD., JILIN Free format text: FORMER OWNER: GUAN TIANYING Effective date: 20120629 Free format text: FORMER OWNER: WANG YUZHI LIU SHUZHEN JILIN AGRICULTURAL UNIVERSITY Effective date: 20120629 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 130118 CHANGCHUN, JILIN PROVINCE TO: 132300 JILIN, JILIN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120629 Address after: 132300 No. 777, West Point Avenue, Panshi Economic Development Zone, Jilin Patentee after: Xidian Pharm Ind Tech Development Co., Ltd., Jilin Prov. Address before: 130118 Jilin province Changchun City Panshi street in Nanguan District of East Ring Road South four Commission 51 group 7 Building No. 104 Co-patentee before: Wang Yuzhi Patentee before: Guan Tianying Co-patentee before: Liu Shuzhen Co-patentee before: Jilin Agricultural University |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20001227 |